BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Sep 10, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts PGK1-knockout mice expressing an SP-C variant could be used to study the biology of idiopathic pulmonary fibrosis (IPF) and screen for therapies. Mice with inducible knockout of PGK1 that systemically expressed...
BC Innovations | Dec 11, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke; sepsis Phosphoglycerate kinase 1 (PGK1); heat shock protein 90 (Hsp90) In vitro and rodent models suggest the generic hypertension drug terazosin could help treat...
BC Innovations | Dec 11, 2014
Targets & Mechanisms

Terazosin reborn

In searching for compounds to treat stroke or sepsis, a Chinese team has found a new activity-and possibly a new indication-for an old drug. Terazosin, a generic a-blocker used in hypertension, inhibited apoptosis and extended...
BioCentury | Dec 5, 2011
Product Development

Change-up for BATTER-UP

A year after starting a biomarker study in rheumatoid arthritis, a broad-based consortium has been forced to retool its recruitment strategy. The Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis -Unresponsive Populations Consortium had hoped...
Items per page:
1 - 5 of 5